Nakamoto Inc.

NASDAQ:NAKA

Financial - Capital Markets

Financial Services
$4.45 +0.03%

+$0.00 today

Market cap
$77.44M
Beta
-0.90
P/E (TTM)
-0.2
EPS (TTM)
-$18.22
52W Low $4.05High $679.20

Volume 0.13M

Average 0.24M

NAKA Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Nakamoto Inc.NASDAQ: NAKA

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development remains negative

Q1 FY2026 research & development was $0, compared with $97 a year earlier. Trailing-twelve-month research & development was $4.

Context

  • Research & development amounted to 0.0% of revenue in FY2025, down 13.9 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $1.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMMar 2026
$4-100.0% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Research & Development vs competitors

How NAKA compares with its peers on the latest reported figures

  • NAKA's LTM Mar 2026 research & development of $4 is the 10th highest of the 11 companies compared; the peer median is $34.98M.
  • Its year-over-year change of -100.0% is the lowest of 10, against a peer median of +5.3%.
  • Research & development amounts to 0.0% of revenue for NAKA, versus a peer median of 25.5%.
NAKA Competitors Peer median
Research & Development for NAKA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$152.7M +75.7%+85.3%—
LYELLyell Immunopharma, Inc.LTM Mar 2026$151.83M -11.7%-0.1%489780.6%
DBVTDBV Technologies S.A.LTM Mar 2026$124.71M +42.2%+15.6%—
CLLSCellectis S.A.LTM Mar 2026$94.68M +5.0%-1.4%139.0%
SOPHSOPHiA GENETICS S.A.LTM Mar 2026$35.89M +5.3%-1.7%44.2%
DCTHDelcath Systems, Inc.LTM Mar 2026$34.06M +124.4%+16.3%37.7%
DHDefinitive Healthcare Corp.LTM Mar 2026$31.97M -10.4%-0.1%13.4%
AMRNAmarin Corporation plcLTM Mar 2026$18.45M -6.9%-13.3%8.6%
SLPSimulations Plus, Inc.LTM Feb 2026$9.34M +29.5%+29.0%11.6%
NAKANakamoto Inc.LTM Mar 2026$4 -100.0%—0.0%
AGLAgilon Health, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding NAKA) $34.98M+5.3%-0.1%25.5%

Competitors are the stored peer set for NAKA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.5M3.79M3.77M2.72M1.82M
Cost of Revenue1.59M152.39K226.17K3.56M11.09M
Gross Profit914.92K3.63M3.54M(842.57K)(9.27M)
Gross Margin36.5%96.0%94.0%-31.0%-508.8%
Research & Development002.5K377.73K0
Selling, General & Admin853.58K6.27M5.05M1.91M11.76M
Operating Expenses853.58K6.33M5.16M2.5M187.87M
Depreciation & Amortization63.4K122.01K203.22K220.33K241.99K
EBITDA124.74K(2.42M)(1.36M)(3M)(44.93M)
EBITDA Margin5.0%-63.9%-36.0%-110.4%-2466.7%
Operating Income61.34K(2.69M)(1.62M)(3.35M)(197.14M)
Operating Margin2.4%-71.1%-43.0%-123.1%-10824.0%
Interest Income00000
Interest Expense0055.84K393.45K7.06M
Other Income / Expenses88K152.82K2.76K(270.88K)144.91M
Income Before Tax149.34K(2.54M)(1.62M)(3.62M)(52.23M)
Pre-Tax Margin6.0%-67.1%-42.9%-133.0%-2867.6%
Income Tax Expense00000
Net Income149.34K(2.54M)(1.62M)(3.62M)(52.23M)
Net Margin6.0%-67.1%-42.9%-133.0%-2867.6%
EPS (Basic)0.03(0.43)(0.27)(0.67)(10.40)
EPS (Diluted)0.03(0.43)(0.27)(0.67)(10.40)
Weighted Avg Shares5.97M5.89M5.89M5.39M11.36M
Weighted Avg Shares (Diluted)5.97M5.89M5.89M5.39M11.36M

Nakamoto Inc.

NASDAQ:NAKA

Intrinsic Alpha fair value

Locked

Current Price

$4.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.